Abstract
摘要
相似文献
1
Aldesleukin shows promise.
AIDS Patient Care STDS. 1999 May;13(5):307.
2
Phase III trial of IL-2.
AIDS Patient Care STDS. 1999 Dec;13(12):753-4.
3
Spotlight on interleukin-2 (IL-2, proleukin).
Proj Inf Perspect. 2001 Mar(32):13-5.
4
Aldesleukin therapy in HIV-infected patients.
Am J Health Syst Pharm. 1998 Jul 15;55(14):1520-3. doi: 10.1093/ajhp/55.14.1520.
5
Recombinant Interleukin-2 (rIL-2), aldesleukin.
J Biotechnol. 2002 May 23;95(3):277-80. doi: 10.1016/s0168-1656(02)00019-6.
6
IL-2 immunotherapy does not benefit patients taking antiretrovirals.
AIDS Patient Care STDS. 2009 Mar;23(3):221-2.
7
[HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
Pathol Biol (Paris). 2010 Dec;58(6):403-5. doi: 10.1016/j.patbio.2009.03.005. Epub 2009 May 28.
8
Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
J HIV Ther. 2010 Mar;15(1):15-7.
9
Technology evaluation: BAY-50-4798, Bayer.
Curr Opin Mol Ther. 2004 Apr;6(2):221-7.
10
CYT107 enters Phase II clinical trial in HIV-infected patients.
Immunotherapy. 2010 Nov;2(6):755. doi: 10.2217/imt.10.86.
Zotero 插件